123 related articles for article (PubMed ID: 34058568)
1. The levels of IL-6 and soluble IL-33R are increased in the renal vein during surgery for clear cell renal cell carcinoma.
Gudbrandsdottir G; Aarstad HH; Hjelle KM; Førde K; Reisæter L; Bostad L; Aarstad HJ; Beisland C
Cytokine; 2021 Aug; 144():155586. PubMed ID: 34058568
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC).
Gudbrandsdottir G; Aarstad HH; Bostad L; Hjelle KM; Aarstad HJ; Bruserud Ø; Tvedt THA; Beisland C
Cancer Immunol Immunother; 2021 Jan; 70(1):19-30. PubMed ID: 32621022
[TBL] [Abstract][Full Text] [Related]
3. The correlation between low vitamin D status and renal interleukin-6/STAT3 hyper-activation in patients with clear cell renal cell carcinoma.
Song J; Xu S; Zhang ZH; Chen YH; Gao L; Xie DD; Sun GP; Yu DX; Xu DX
Steroids; 2019 Oct; 150():108445. PubMed ID: 31295461
[TBL] [Abstract][Full Text] [Related]
4. Circulating obesity-driven biomarkers are associated with risk of clear cell renal cell carcinoma: a two-stage, case-control study.
Wang Q; Tu H; Zhu M; Liang D; Ye Y; Chang DW; Long Y; Wu X
Carcinogenesis; 2019 Oct; 40(10):1191-1197. PubMed ID: 31001636
[TBL] [Abstract][Full Text] [Related]
5. Expression of the interleukin 6 receptor in primary renal cell carcinoma.
Costes V; Liautard J; Picot MC; Robert M; Lequeux N; Brochier J; Baldet P; Rossi JF
J Clin Pathol; 1997 Oct; 50(10):835-40. PubMed ID: 9462266
[TBL] [Abstract][Full Text] [Related]
6. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue.
Jabs WJ; Busse M; Krüger S; Jocham D; Steinhoff J; Doehn C
Kidney Int; 2005 Nov; 68(5):2103-10. PubMed ID: 16221209
[TBL] [Abstract][Full Text] [Related]
7. Minimal changes in the systemic immune response after nephrectomy of localized renal masses.
Wald G; Barnes KT; Bing MT; Kresowik TP; Tomanek-Chalkley A; Kucaba TA; Griffith TS; Brown JA; Norian LA
Urol Oncol; 2014 Jul; 32(5):589-600. PubMed ID: 24768357
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
9. Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy.
Nukui A; Masuda A; Abe H; Arai K; Yoshida KI; Kamai T
BMC Cancer; 2017 May; 17(1):372. PubMed ID: 28545581
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis.
Fu Q; Chang Y; An H; Fu H; Zhu Y; Xu L; Zhang W; Xu J
Br J Cancer; 2015 Dec; 113(11):1581-9. PubMed ID: 26554658
[TBL] [Abstract][Full Text] [Related]
11. Immunobiochemical profile of clear cell renal cell carcinoma (ccRCC): A preliminary study.
Vargová D; Dargaj J; Fraňová S; Dohál M; Ľupták J; Švihra J; Briš L; Grendár M; Šutovská M
Gen Physiol Biophys; 2023 Sep; 42(5):387-401. PubMed ID: 37702445
[TBL] [Abstract][Full Text] [Related]
12. Obesity induces limited changes to systemic and local immune profiles in treatment-naive human clear cell renal cell carcinoma.
Gibson JT; Norris KE; Wald G; Buchta Rosean CM; Thomas LJ; Boi SK; Bertrand LA; Bing M; Gordetsky JB; Deshane J; Li P; Brown JA; Nepple KG; Norian LA
PLoS One; 2020; 15(5):e0233795. PubMed ID: 32469992
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors.
Guan X; Liu Z; Zhang J; Jin X
Adv Clin Exp Med; 2018 Jul; 27(7):947-953. PubMed ID: 29905412
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
15. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
16. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma.
Dosquet C; Schaetz A; Faucher C; Lepage E; Wautier JL; Richard F; Cabane J
Eur J Cancer; 1994; 30A(2):162-7. PubMed ID: 8155390
[TBL] [Abstract][Full Text] [Related]
17. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
18. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
Desar IM; Stillebroer AB; Oosterwijk E; Leenders WP; van Herpen CM; van der Graaf WT; Boerman OC; Mulders PF; Oyen WJ
J Nucl Med; 2010 Nov; 51(11):1707-15. PubMed ID: 20956472
[TBL] [Abstract][Full Text] [Related]
19. [Changes of proinflammatory cytokines and their receptors in serum from patients with pulmonary tuberculosis].
Tang S; Xiao H; Fan Y; Wu F; Zhang Z; Li H; Yang Y
Zhonghua Jie He He Hu Xi Za Zhi; 2002 Jun; 25(6):325-9. PubMed ID: 12126553
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
Kocarslan S; Guldur ME; Ekinci T; Ciftci H; Ozardali HI
J Cancer Res Ther; 2014; 10(4):1076-81. PubMed ID: 25579557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
